Posted by Michael Wonder on 31 Oct 2018
ICER posts draft scoping document for the assessment of siponimod for the treatment of secondary progressive multiple sclerosis
31 October 2018 - Document open to public comment until 20 November 2018.
The ICER has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of siponimod (Novartis), which is currently undergoing FDA review as a potential treatment for secondary progressive multiple sclerosis, with an approval decision expected in March 2019.
ICER's report on siponimod will be the subject of a May 2019 meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER's three independent evidence appraisal committees.
